Bioharvest Sciences

BioHarvest Sciences Inc.(Nasdaq: BHST) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 17 years and >$100M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a “target optimized” combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Biologics+ CDMO Services: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, nutrition, cosmetics, and nutraceutical partners to develop proprietary compounds with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. Direct to Consumer Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has now exceeded daily users (>$50M USD Revenue since 2021 launch). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs.